Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

General Mills

Netflix

Walmart

These high-quality companies have all made it through tough times before -- and will again.

These 4 Top Stocks Are Bear-Market Tested

Inovio Pharmaceuticals

Moderna

Regeneron Pharmaceuticals

Biotech stocks related to the coronavirus have surged -- but once the outbreak wanes, future gains will depend on the rest of their pipelines.

Is It Too Late to Buy Coronavirus Biotech Stocks?

Remdesivir appears to have helped coronavirus patients, and the drug looks poised to boost GILD stock.
The post Remdesivir, Other Positive Catalysts Should Lift Gilead Stock appeared first on InvestorPlace.

Remdesivir, Other Positive Catalysts Should Lift Gilead Stock

FUJIFILM Holdings Corp

Early studies show the influenza treatment significantly shortens coronavirus illnesses and improves lung function in patients.

Japanese-Developed Flu Drug Avigan Seems Effective Against COVID-19

Shares of GILD stock popped Thursday after an analyst suggested Gilead Sciences' experimental coronavirus treatment would succeed in clinical studies. It's currently in five studies.

Covid Report: Does Gilead Have A Billion-Dollar Drug In Coronavirus?

Covid Report: Gilead Surges On Trump Backing For Coronavirus Drug

Enanta Pharmaceuticals

Eli Lilly

Roche Holding AG

Sanofi

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?

BioNTech SE

GlaxoSmithKline

Pfizer

Takeda Pharmaceutical

The battle to defeat the coronavirus will be won. But victory won't come as quickly as anyone would like.

Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News

A senior research analyst at Piper Sandler believes Gilead Sciences Inc.'s (NASDAQ: GILD) Remdesivir antiviral may soon be approved for COVID-19 treatment.

Analyst Says Gilead's Remdesivir Could Be Approved 'Within Months' For COVID-19 Treatment

If a safe and effective treatment for COVID-19 is close at hand, it will likely come from one of these two biotechs.

Better Coronavirus Stock: Gilead Sciences or Regeneron Pharmaceuticals?

The Senate approved the proposed relief package on Wednesday, with the president signing it shortly after.

Trump Signs Coronavirus Relief Bill Into Law

The big biotech has a drug that struck out on one super-contagious disease but could be the best option on the scene for treating another.

Why Is Everyone Talking About Gilead Sciences?

Gilead Sciences - Even Not Counting COVID-19, The Company Has Significant Potential

Relmada Therapeutics Inc

Trulieve Cannabis Corp.

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.

Top Pharmaceutical Stocks for Q2 2020

Crown Castle International

Clorox

Landbridge Co LLC

Newmont Mining

Rollins

SBA Communications

While coronavirus fears have killed the stock market this year, these nine best stocks for 2020 have bucked the trend.

The 9 Best Stocks to Buy for 2020’s Market Meltdown

AbbVie

AbbVie, Gilead Sciences, and Pfizer should help immunize your portfolio against the ravages of the coronavirus.

Coronavirus Correction: 3 Must-Own Dividend Stocks

HCA Healthcare

Teladoc

Health groups are asking hospitals to decrease or even halt elective surgeries as the coronavirus pandemic heats up.

Will Your Elective Surgery Be Delayed by Coronavirus?

Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.

Gilead Up as Remdesivir Shows Promise in Treating Coronavirus

The EU's medical regulator is looking to help, and to gain insight about where its resources can best be deployed.

European Medicines Agency Offers Free Advice for Drugmakers Working on Coronavirus Treatments

Gilead’s stock has fared better than the broader markets through the current coronavirus and oil price war crisis, with the stock currently up by about 10% since early February, after the WHO declared a global health emergency.

Why Is Coronavirus Helping Gilead’s Stock?

12 Reasons Gilead With Remdesivir Is My Best COVID-19 Bet

Vertex Pharmaceuticals

Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.

4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy

Amgen

Biogen

CRISPR Therapeutics

Editas Medicine

Innoviva

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

Altimmune

Aytu BioScience

Co-Diagnostics

Quest Diagnostics

Lakeland Industries

NanoViricides

Novavax

Zoom Video

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

How Coronavirus Stocks Were Holding Up in Monday’s Sell-Off

Gilead's antiviral medication remdesivir could radically change the course of the ongoing COVID-19 outbreak.

News for Gilead Sciences Stock (GILD)